Continuum Advisory, LLC Supernus Pharmaceuticals, Inc. Transaction History
Continuum Advisory, LLC
- $760 Million
- Q4 2024
A detailed history of Continuum Advisory, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Continuum Advisory, LLC holds 17 shares of SUPN stock, worth $569. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17
Previous 17
-0.0%
Holding current value
$569
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
303Shares Held
60.6MCall Options Held
22.3KPut Options Held
6K-
Black Rock Inc. New York, NY10.4MShares$348 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.15MShares$206 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.84MShares$162 Million2.47% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.88MShares$96.5 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.63MShares$88.1 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.79B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...